Company Description
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD).
It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).
The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies.
In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs.
The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023.
Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
| Country | United States |
| Founded | 2013 |
| IPO Date | Apr 7, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 30 |
| CEO | Dr. Cameron Turtle DPHIL, Ph.D. |
Contact Details
Address: 221 Crescent Street, Building 23, Suite 105 Waltham, Massachusetts 02453 United States | |
| Phone | (617) 651-5940 |
| Website | spyre.com |
Stock Details
| Ticker Symbol | SYRE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001636282 |
| ISIN Number | US00773J2024 |
| Employer ID | 46-4312787 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Cameron Turtle DPHIL, Ph.D. | Chief Executive Officer and Director |
| Scott L. Burrows | Chief Financial Officer |
| Heidy Abreu King-Jones J.D., L.L.M. | Chief Legal Officer and Corporate Secretary |
| Dr. Janet Gunzner-Toste M.B.A., Ph.D. | Senior Vice President of Operations |
| Brian Connolly | Chief Technical Officer |
| Eric McIntyre | Vice President of Finance and Investor Relations |
| James Myers | Vice President of Quality and Compliance |
| Dr. Kelly Boothe Ph.D. | Senior Director of Corporate Communications and Investor Relations |
| Dr. Justin LaFountaine Ph.D. | Senior Vice President of Corporate Development |
| Melissa Cooper | Senior Vice President of People |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 25, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Apr 25, 2024 | 8-K | Current Report |
| Apr 23, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Apr 19, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Apr 2, 2024 | ARS | Filing |
| Apr 1, 2024 | EFFECT | Notice of Effectiveness |
| Apr 1, 2024 | EFFECT | Notice of Effectiveness |
| Apr 1, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 27, 2024 | POS AM | Post-Effective amendments for registration statement |
| Mar 27, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |